Kyntra Bio Inc (NASDAQ:KYNB) Given Average Rating of “Moderate Buy” by Analysts

Shares of Kyntra Bio Inc (NASDAQ:KYNB) have been assigned a consensus rating of “Moderate Buy” from the five brokerages that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, two have assigned a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $32.50.

Several equities research analysts have weighed in on the company. Rodman & Renshaw started coverage on Kyntra Bio in a research note on Tuesday, June 9th. They set a “buy” rating and a $30.00 target price for the company. Oppenheimer assumed coverage on Kyntra Bio in a research report on Monday, July 6th. They set an “outperform” rating and a $35.00 price objective for the company. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Kyntra Bio in a research note on Tuesday, June 16th. Finally, Wall Street Zen raised Kyntra Bio from a “sell” rating to a “hold” rating in a research note on Saturday, April 18th.

Kyntra Bio Stock Performance

Shares of Kyntra Bio stock opened at $6.79 on Friday. The stock’s 50 day moving average price is $7.07. Kyntra Bio has a 1-year low of $6.32 and a 1-year high of $12.60. The company has a market cap of $27.50 million, a P/E ratio of 0.17 and a beta of 0.96.

Institutional Trading of Kyntra Bio

A hedge fund recently bought a new stake in Kyntra Bio stock. ADAR1 Capital Management LLC purchased a new stake in Kyntra Bio Inc (NASDAQ:KYNB) in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 10,469 shares of the company’s stock, valued at approximately $71,000. ADAR1 Capital Management LLC owned about 0.26% of Kyntra Bio as of its most recent filing with the Securities and Exchange Commission. 72.71% of the stock is currently owned by institutional investors.

Kyntra Bio Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.